MX2023003855A - Metodos para reducir la expresion de apociii. - Google Patents
Metodos para reducir la expresion de apociii.Info
- Publication number
- MX2023003855A MX2023003855A MX2023003855A MX2023003855A MX2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A MX 2023003855 A MX2023003855 A MX 2023003855A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- fcs
- reducing apociii
- shtg
- fpl
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000016667 Familial chylomicronemia syndrome Diseases 0.000 abstract 4
- 208000003929 Familial Partial Lipodystrophy Diseases 0.000 abstract 3
- 102100030970 Apolipoprotein C-III Human genes 0.000 abstract 2
- 101000793223 Homo sapiens Apolipoprotein C-III Proteins 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 abstract 1
- 208000004998 Abdominal Pain Diseases 0.000 abstract 1
- 108010004103 Chylomicrons Proteins 0.000 abstract 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 241000764238 Isis Species 0.000 abstract 1
- 206010027374 Mental impairment Diseases 0.000 abstract 1
- 206010016256 fatigue Diseases 0.000 abstract 1
- 206010019847 hepatosplenomegaly Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 abstract 1
- 238000012739 integrated shape imaging system Methods 0.000 abstract 1
- 208000024866 recurrent acute pancreatitis Diseases 0.000 abstract 1
- 230000000630 rising effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3525—MOE, methoxyethoxy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063087095P | 2020-10-02 | 2020-10-02 | |
| PCT/US2021/052001 WO2022072244A1 (en) | 2020-10-02 | 2021-09-24 | Methods for reducing apociii expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003855A true MX2023003855A (es) | 2023-04-14 |
Family
ID=80950871
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003855A MX2023003855A (es) | 2020-10-02 | 2021-09-24 | Metodos para reducir la expresion de apociii. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240033280A1 (enExample) |
| EP (1) | EP4221720A4 (enExample) |
| JP (1) | JP2023543898A (enExample) |
| KR (1) | KR20230079394A (enExample) |
| CN (1) | CN116348125A (enExample) |
| AU (1) | AU2021353849A1 (enExample) |
| BR (1) | BR112023004012A2 (enExample) |
| IL (1) | IL300882A (enExample) |
| MX (1) | MX2023003855A (enExample) |
| WO (1) | WO2022072244A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2024097861A1 (en) * | 2022-11-02 | 2024-05-10 | Ionis Pharmaceuticals, Inc. | Methods for modulating complement factor b expression |
| KR20250173600A (ko) | 2023-03-17 | 2025-12-10 | 옥시토프 파마 비.브이. | 항-포스포콜린 항체 및 그 사용 방법 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7598227B2 (en) * | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
| DK2956176T3 (en) * | 2013-02-14 | 2018-08-27 | Ionis Pharmaceuticals Inc | MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS |
| CN107405358A (zh) * | 2015-02-27 | 2017-11-28 | Ionis制药公司 | 调节脂肪代谢障碍群体中的载脂蛋白c‑iii(apociii)表达 |
| PL4119569T3 (pl) * | 2015-11-06 | 2024-11-18 | Ionis Pharmaceuticals, Inc. | Sprzężone związki antysensowne do zastosowania w terapii |
-
2021
- 2021-09-24 US US18/247,567 patent/US20240033280A1/en active Pending
- 2021-09-24 JP JP2023520059A patent/JP2023543898A/ja active Pending
- 2021-09-24 EP EP21876250.8A patent/EP4221720A4/en active Pending
- 2021-09-24 IL IL300882A patent/IL300882A/en unknown
- 2021-09-24 KR KR1020237013301A patent/KR20230079394A/ko active Pending
- 2021-09-24 CN CN202180066569.6A patent/CN116348125A/zh active Pending
- 2021-09-24 AU AU2021353849A patent/AU2021353849A1/en active Pending
- 2021-09-24 MX MX2023003855A patent/MX2023003855A/es unknown
- 2021-09-24 BR BR112023004012A patent/BR112023004012A2/pt unknown
- 2021-09-24 WO PCT/US2021/052001 patent/WO2022072244A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20240033280A1 (en) | 2024-02-01 |
| WO2022072244A1 (en) | 2022-04-07 |
| JP2023543898A (ja) | 2023-10-18 |
| EP4221720A4 (en) | 2024-11-13 |
| EP4221720A1 (en) | 2023-08-09 |
| IL300882A (en) | 2023-04-01 |
| AU2021353849A8 (en) | 2023-03-30 |
| CN116348125A (zh) | 2023-06-27 |
| AU2021353849A1 (en) | 2023-03-23 |
| BR112023004012A2 (pt) | 2023-04-25 |
| KR20230079394A (ko) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023003855A (es) | Metodos para reducir la expresion de apociii. | |
| Braga et al. | Clinical evidence for pharmaconutrition in major elective surgery | |
| Henrotin et al. | Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations | |
| Pironi et al. | Safety and efficacy of home parenteral nutrition for chronic intestinal failure: a 16-year experience at a single centre | |
| Goldberg et al. | Intra-articular hyaluronans: the treatment of knee pain in osteoarthritis | |
| BR112014009837A8 (pt) | uso eficaz da levedura e extrato de levedura | |
| BR112015025390A2 (pt) | Composição, métodos para isolar célula tronco, para tratar um indivíduo e um paciente, para reduzir um depósito de gordura, para dissociar um tecido e uma matriz de proteína, para tratar ou curar uma cicatriz ou uma ferida, e para isolar células ilhotas, vetor de expressão, composição farmacêutica, formulação de liberação temporizada, e, kit | |
| DE60326043D1 (de) | Methode zur verhinderung oder linderung von symptomen bei unzureichender aufnahme aus dem gastrointestinaltrakt | |
| Lin et al. | The effects of protease, xylanase, and xylo-oligosaccharides on growth performance, nutrient utilization, short-chain fatty acids, and microbiota in Eimeria-challenged broiler chickens fed low-protein diet | |
| Jiang et al. | Inhibition of penile tunica albuginea myofibroblasts activity by adipose-derived stem cells | |
| Chaitow | Soft-tissue Manipulation: A Practitioner's Guide to the Diagnosis and Treatment of Soft-tissue Dysfunction and Reflex Activity | |
| Maltsev et al. | Vitamin D and immunity | |
| US20210340177A1 (en) | Bioactive peptides having high binding affinity to human muscular nicotinic acetylcholine receptor | |
| BRPI0410761A (pt) | uso de leucina, e, composição para administração entérica a pacientes | |
| Honda et al. | Drug eruption following high-calorie infusion: a possible systemic type IV allergic reaction to sulphites | |
| Lin et al. | Transfer of the superior portion of the pectoralis major flap for restoration of shoulder abduction | |
| Mills | The heart failure frequent flyer: an urban legend | |
| AU2019100077A4 (en) | Treatment for gastrointestinal diseases, depression, and anxieties | |
| Xianjin et al. | Influence of wuqinxi on proprioceptive sensation and body balance function of female patients with knee osteoarthritis | |
| Shokrzade et al. | Protective Effect of Methanol and Hot-water Extraction from Trametes versicolor on Ethanol-induced Liver Toxicity in Mice. | |
| In et al. | Treatment with Vitis vinifera extract for controlling ascites and local swelling in snakebites | |
| Sawada | Editorial Comment to Clinical guidelines for interstitial cystitis/bladder pain syndrome. | |
| MU | FELE | |
| KARNIB | The Effects of Caloric Vestibular Stimulation on Risk-Taking Propensity and Interoception in Healthy Participants | |
| Maamoun et al. | Herbal antidotes for poisoning: research into the potential of local or traditional plants as natural antidotes for scorpion envenomation |